September 2010 in “Institutional Repositories DataBase (IRDB)” Sorafenib can cause a temporary skin condition that goes away after stopping the drug.
11 citations
,
December 2013 in “Clinical and Experimental Dermatology” This article reviews the use of sorafenib, a multikinase inhibitor, for treating certain carcinomas, noting that cutaneous toxicity during treatment may indicate successful antitumor activity; however, it reports no new clinical results.
13 citations
,
June 2008 in “International Journal of Dermatology” This case study reports a unique and severe papulopustular eruption, likely induced by sorafenib treatment in a patient with metastatic renal cancer, which manifested as hyperkeratotic spicules and improved with cessation of the drug.
In this case report, a patient on low-dose sorafenib for hepatocellular carcinoma developed a rare and severe facial acneiform eruption without other skin side effects, which improved only minimally with topical treatment.
14 citations
,
August 2017 in “International Journal of Immunopathology and Pharmacology” This case report describes a patient with painful skin lesions during sorafenib treatment whose symptoms improved after receiving photodynamic therapy, suggesting it might help manage similar refractory skin toxicity cases.